EFFECT OF 104 WEEKS OF MIRIKIZUMAB TREATMENT ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES AMONG PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Bruce E. Sands  ¹     Vipul Jairath  ²     Theresa Hunter Gibble  ³     Zhantao Lin  ³     Kristina Traxler  ³     Marijana Protic  ³     Rebecca Hozak  ³     Brian G. Feagan  ⁴     Alessandro Armuzzi  ⁵     Peter Bossuyt  ^6    
1 Icahn School of Medicine at Mount Sinai, New York, United States
² Western University & London Health Sciences Centre, London, Canada
³ Eli Lilly and Company, Indianapolis, United States
⁴ The University of Western Ontario, London, Canada
⁵ IBD Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
⁶ Imelda General Hospital, Bonheiden, Belgium

Topic
IBD

Session
IL-23: Many but different? (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)